NASDAQ:TVTX Travere Therapeutics Q3 2026 Earnings Report $56.57 -2.31 (-3.92%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Travere Therapeutics EPS ResultsActual EPSN/AConsensus EPS $0.03Beat/MissN/AOne Year Ago EPSN/ATravere Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$195.68 millionBeat/MissN/AYoY Revenue GrowthN/ATravere Therapeutics Announcement DetailsQuarterQ3 2026Date10/29/2026TimeAfter Market ClosesConference Call DateThursday, October 29, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Travere Therapeutics Earnings HeadlinesKuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmSeptember 30 at 9:58 AM | prnewswire.comCritical Survey: Travere Therapeutics (NASDAQ:TVTX) & Vericel (NASDAQ:VCEL)September 27, 2026 | americanbankingnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 1 at 1:00 AM | Weiss Ratings (Ad)Travere Therapeutics (NASDAQ:TVTX) Earns "Outperform" Rating from WedbushSeptember 24, 2026 | americanbankingnews.comTravere Therapeutics (TVTX) Sets CEO Handover For December 2026September 22, 2026 | finance.yahoo.comTravere Therapeutics (TVTX) Stock May Trade Above Fair Value TodaySeptember 22, 2026 | finance.yahoo.comSee More Travere Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Travere Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Travere Therapeutics and other key companies, straight to your email. Email Address About Travere TherapeuticsTravere Therapeutics (NASDAQ:TVTX) is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work centers on conditions with limited treatment options, including IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment approved in the United States for certain adults with primary IgAN who are at risk of disease progression. The company is also evaluating sparsentan and other potential therapies in additional kidney-disease indications, including FSGS, through clinical development programs. Originally founded as Retrophin, the company adopted the name Travere Therapeutics in 2020. Based in San Diego, California, Travere serves patients and healthcare professionals primarily through its U.S. commercial operations while pursuing clinical development and regulatory opportunities in international markets. Neil McFarlane serves as the company’s chief executive officer.View Travere Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
